Terms: = Colorectal cancer AND MSH2, COCA1, 4436, ENSG00000095002, HNPCC, FCC1, HNPCC1, P43246 AND Clinical Outcome
19 results:
1. msh2-deficient prostate tumours have a distinct immune response and clinical outcome compared to msh2-deficient colorectal or endometrial cancer.
McCoy P; Mangiola S; Macintyre G; Hutchinson R; Tran B; Pope B; Georgeson P; Hong MKH; Kurganovs N; Lunke S; Clarkson MJ; Cmero M; Kerger M; Stuchbery R; Chow K; Haviv I; Ryan A; Costello AJ; Corcoran NM; Hovens CM
Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):1167-1180. PubMed ID: 34108644
[TBL] [Abstract] [Full Text] [Related]
2. Patients with hMLH1 or/and hmsh2-deficient Metastatic colorectal cancer Are Associated with Reduced Levels of Vascular Endothelial Growth Factor-1 Expression and Higher Response Rate to Irinotecan-based Regimen.
Bendardaf R; Sharif-Askari FS; Sharif-Askari NS; Syrjänen K; Pyrhönen S
Anticancer Res; 2018 Nov; 38(11):6399-6404. PubMed ID: 30396964
[TBL] [Abstract] [Full Text] [Related]
3. DNA mismatch repair deficiency but not ARID1A loss is associated with prognosis in small intestinal adenocarcinoma.
González I; Goyal B; Xia MD; Pai RK; Ma C
Hum Pathol; 2019 Mar; 85():18-26. PubMed ID: 30381262
[TBL] [Abstract] [Full Text] [Related]
4. clinical Impact of Mismatch Repair Protein Testing on outcome of Early Staged colorectal Carcinomas.
Gandhi JS; Goswami M; Sharma A; Tanwar P; Gupta G; Gupta N; Pasricha S; Mehta A; Singh S; Agarwal M; Gupta N
J Gastrointest Cancer; 2018 Dec; 49(4):406-414. PubMed ID: 28585041
[TBL] [Abstract] [Full Text] [Related]
5. Mismatch repair status may predict response to adjuvant chemotherapy in resectable pancreatic ductal adenocarcinoma.
Riazy M; Kalloger SE; Sheffield BS; Peixoto RD; Li-Chang HH; Scudamore CH; Renouf DJ; Schaeffer DF
Mod Pathol; 2015 Oct; 28(10):1383-9. PubMed ID: 26226846
[TBL] [Abstract] [Full Text] [Related]
6. Microsatellite instability testing and its role in the management of colorectal cancer.
Kawakami H; Zaanan A; Sinicrope FA
Curr Treat Options Oncol; 2015 Jul; 16(7):30. PubMed ID: 26031544
[TBL] [Abstract] [Full Text] [Related]
7. Methylation of the polycomb group target genes is a possible biomarker for favorable prognosis in colorectal cancer.
Dallol A; Al-Maghrabi J; Buhmeida A; Gari MA; Chaudhary AG; Schulten HJ; Abuzenadah AM; Al-Ahwal MS; Sibiany A; Al-Qahtani MH
Cancer Epidemiol Biomarkers Prev; 2012 Nov; 21(11):2069-75. PubMed ID: 23010642
[TBL] [Abstract] [Full Text] [Related]
8. Microsatellite instability in colorectal cancer: from molecular oncogenic mechanisms to clinical implications.
Zaanan A; Meunier K; Sangar F; Fléjou JF; Praz F
Cell Oncol (Dordr); 2011 Jun; 34(3):155-76. PubMed ID: 21484480
[TBL] [Abstract] [Full Text] [Related]
9. Clinicopathological and molecular characterization of colorectal micropapillary carcinoma.
Verdú M; Román R; Calvo M; Rodón N; García B; González M; Vidal A; Puig X
Mod Pathol; 2011 May; 24(5):729-38. PubMed ID: 21336262
[TBL] [Abstract] [Full Text] [Related]
10. A MLH1 polymorphism that increases cancer risk is associated with better outcome in sporadic colorectal cancer.
Nejda N; Iglesias D; Moreno Azcoita M; Medina Arana V; González-Aguilera JJ; Fernández-Peralta AM
Cancer Genet Cytogenet; 2009 Sep; 193(2):71-7. PubMed ID: 19665066
[TBL] [Abstract] [Full Text] [Related]
11. Comparison of survival between patients with hereditary non polyposis colorectal cancer (hnpcc) and sporadic colorectal cancer.
Haghighi MM; Vahedi M; Mohebbi SR; Pourhoseingholi MA; Fatemi SR; Zali MR
Asian Pac J Cancer Prev; 2009; 10(2):209-12. PubMed ID: 19537885
[TBL] [Abstract] [Full Text] [Related]
12. Prognostic significance of histological features and biological parameters in stage I (pT1 and pT2) colorectal adenocarcinoma.
Losi L; Ponti G; Gregorio CD; Marino M; Rossi G; Pedroni M; Benatti P; Roncucci L; de Leon MP
Pathol Res Pract; 2006; 202(9):663-70. PubMed ID: 16860493
[TBL] [Abstract] [Full Text] [Related]
13. Immunohistochemical test for MLH1 and msh2 expression predicts clinical outcome in stage II and III colorectal cancer patients.
Lanza G; Gafà R; Santini A; Maestri I; Guerzoni L; Cavazzini L
J Clin Oncol; 2006 May; 24(15):2359-67. PubMed ID: 16710035
[TBL] [Abstract] [Full Text] [Related]
14. Hereditary ovarian cancer.
Prat J; Ribé A; Gallardo A
Hum Pathol; 2005 Aug; 36(8):861-70. PubMed ID: 16112002
[TBL] [Abstract] [Full Text] [Related]
15. Hereditary risk of women's cancers.
Frank TS; Critchfield GC
Best Pract Res Clin Obstet Gynaecol; 2002 Oct; 16(5):703-13. PubMed ID: 12475549
[TBL] [Abstract] [Full Text] [Related]
16. Microsatellite alterations in serum DNA of patients with colorectal cancer.
Kölble K; Ullrich OM; Pidde H; Barthel B; Diermann J; Rudolph B; Dietel M; Schlag PM; Scherneck S
Lab Invest; 1999 Sep; 79(9):1145-50. PubMed ID: 10496533
[TBL] [Abstract] [Full Text] [Related]
17. colorectal carcinoma in different age groups: a population-based investigation.
Fante R; Benatti P; di Gregorio C; De Pietri S; Pedroni M; Tamassia MG; Percesepe A; Rossi G; Losi L; Roncucci L; Ponz de Leon M
Am J Gastroenterol; 1997 Sep; 92(9):1505-9. PubMed ID: 9317073
[TBL] [Abstract] [Full Text] [Related]
18. Survival analysis in families affected by hereditary non-polyposis colorectal cancer.
Percesepe A; Benatti P; Roncucci L; Sassatelli R; Fante R; Ganazzi D; Bellacosa A; Genuardi M; Neri G; Viel A; Ponz de Leon M
Int J Cancer; 1997 May; 71(3):373-6. PubMed ID: 9139871
[TBL] [Abstract] [Full Text] [Related]
19. Frequency and clinical features of multiple tumors of the large bowel in the general population and in patients with hereditary colorectal carcinoma.
Fante R; Roncucci L; Di GregorioC ; Tamassia MG; Losi L; Benatti P; Pedroni M; Percesepe A; De Pietri S; Ponz de Leon M
Cancer; 1996 May; 77(10):2013-21. PubMed ID: 8640664
[TBL] [Abstract] [Full Text] [Related]
